Caris Life Sciences Released Enhanced Liquid Biopsy Platform
The new blood-based test provides a molecular profile to help guide precision oncology decisions for patients.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust that new genetic blood tests reliably improve cancer treatment decisions?
Caris Life Sciences has launched an enhanced version of its Caris Assure liquid biopsy platform. The updated assay utilizes a single blood draw to generate a comprehensive molecular profile for patients facing cancer.
Why it matters
The platform is designed to provide deeper molecular insights that may support more informed precision oncology treatment decisions. By simplifying the diagnostic process into a single draw, it aims to streamline how clinicians gather critical data for patient care.
The assay integrates Whole Exome Sequencing, Whole Transcriptome Sequencing, and whole-blood analysis into one process. While this approach is now available, its comparative efficacy against standard diagnostic pathways remains under investigation.
The players
Caris Life Sciences
An Irving, Texas-based biotechnology company focused on precision medicine and molecular profiling technologies for oncology.
The details
The Caris Assure platform functions by combining Whole Exome and Whole Transcriptome sequencing with whole-blood analysis to identify tumor-related genetic changes. By consolidating these analyses into one process, the platform seeks to capture a broad view of a tumor's molecular architecture from a single sample. This allows clinicians to assess complex genetic data that might otherwise require multiple or more invasive testing methods.
Timeline
September 29, 2026: Caris Life Sciences launched the enhanced Caris Assure assay.
Health Landscape
This development aligns with the shift toward less invasive diagnostic tools in precision medicine. It marks a continued effort to improve the utility of liquid biopsies, which are increasingly positioned as key assets alongside traditional tissue-based testing in the oncology landscape.
If you are currently navigating treatment decisions, the utility of liquid biopsy platforms like this is a relevant topic to discuss with your oncologist. Ask your care team whether such molecular profiling is appropriate for your specific cancer type and clinical situation.
The takeaway
Liquid biopsy technology continues to evolve toward more comprehensive and efficient profiling. Keep this development in mind as a potential tool to discuss during consultations regarding genetic testing and personalized cancer treatment pathways.
Further reading
For more information on diagnostic advancements, visit Cancer.
Live Poll
Do you trust that new genetic blood tests reliably improve cancer treatment decisions?
